English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims  Anaemia and iron deficiency are constituents of the cardio‐renal syndrome in chronic heart failure ( CHF ). We investigated the effects of i.v. iron in iron‐deficient  CHF  patients on renal function, and the efficacy and safety of this therapy in patients with renal dysfunction.    Methods and results  The  FAIR‐HF  trial randomized 459  CHF  patients with iron deficiency (ferritin <100 µg/L, or between 100 and 299 µg/L if transferrin saturation was <20%): 304 to i.v. ferric carboxymaltose ( FCM ) and 155 to placebo, and followed‐up for 24 weeks. Renal function was assessed at baseline and at weeks 4, 12, and 24, using the estimated glomerular filtration rate ( eGFR ,  mL /min/1.73 m 2 ), calculated from the Chronic Kidney Disease Epidemiology Collaboration ( CKD–EPI ) formula. At baseline, renal function was similar between groups (62.4 ± 20.6 vs. 62.9 ± 23.4  mL /min/1.73 m 2 ,  FCM  vs. placebo). Compared with placebo, treatment with  FCM  was associated with an increase in  eGFR  [treatment effect: week 4, 2.11 ± 1.21 ( P  = 0.082); week 12, 2.41 ± 1.33 ( P  = 0.070); and week 24, 2.98 ± 1.44  mL /min/1.73 m 2  ( P  = 0.039)]. This effect was seen in all pre‐specified subgroups ( P  > 0.20 for interactions). No interaction between the favourable effects of  FCM  and baseline renal function was seen for the primary endpoints [improvement in Patient Global Assessment ( P  = 0.43) and  NYHA  class ( P  = 0.37) at 24 weeks]. Safety and adverse event profiles were similar in patients with baseline  eGFR  <60 and ≥60  mL /min/1.73 m 2 .    Conclusions  Treatment of iron deficiency in  CHF  patients with i.v.  FCM  was associated with an improvement in renal function.  FCM  therapy was effective and safe in  CHF  patients with renal dysfunction.

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR‐HF study